FDA approved Rystiggo (rozanolixizumab-noli) for treating generalized myasthenia gravis (MG) in adult patients who are anti-acetylcholine receptor or antimuscle-specific tyrosine kinase antibody positive.
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that
You are viewing a robot-friendly page.Click hereto reload in standard format.